Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERMES trial of ziltivekimab in heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
CTR20233203Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) and heart failure with preserved ejection fraction (HFpEF) comparing Ziltivekimab with Ziltivekimab placebo (2 arms). Primary endpoint: Time to first composite heart failure endpoint. Started Nov 2023; status: active.
02
Drugs
ziltivekimab
03
Conditions
chronic heart failure (CHF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20233203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233203.